Comparison of Crystalloid and Colloid I.V Fluid Therapy in Prevention of Paracentesis Induced Circulatory Dysfunction (PICD) and Renal Dysfunction in Patients With Decompensated Liver Cirrhosis in Egypt: a Randomized Piolet Study

Ascites Clinical Trial

Official title:
Comparison of Crystalloid and Colloid I.V Fluid Therapy in Prevention of Paracentesis Induced Circulatory Dysfunction (PICD) and Renal Dysfunction in Patients With Decompensated Liver Cirrhosis in Egypt: a Randomized Piolet Study

Status Not yet recruiting

Clinical Trial Summary

2.2 Aim(s) of the Research (50 words max): To Compare between crystalloid and colloid I.V fluid therapy in the prevention of paracentesis induced circulatory dysfunction (PICD) and renal dysfunction in patients with decompensated liver cirrhosis in Egypt. To evaluate systemic vascular resistance in cirrhotic patients with tense ascites before and after therapeutic paracentesis.

Clinical Trial Description

Background (Research Question, Available Data from the literature, Current strategy for dealing with the problem, Rationale of the research that paves the way to the aim(s) of the work). (200-250 words max.) In the advanced stages of cirrhosis, there is pronounced arterial vasodilatation that further worsens by therapeutic paracentesis which plays a major role in causing circulatory dysfunction (El-Motey et al. 2013). Paracentesis-induced circulatory dysfunction (PICD) in cirrhotics with tense ascites develops in the majority of patients not receiving plasma volume expansion (Hamdy et al.,2014). Paracentesis induced circulatory dysfunction (PICD) will induce pronounced arterial vasodilatation in cirrhotic patients with tense ascites which can be prevented by the infusion of albumin, (Arora et al.,2020). albumin infusion is highly effective in preventing this disorder. However, albumin substitution is costly and holds the theoretical risk of infectious complications and allergic reactions (Arora et al.,2020). Various vasoconstrictors have also been used to prevent PICD such as terlipressin and noradrenaline. However, terlipressin is expensive and not available in some countries, and the use of noradrenaline requires intravenous (IV) infusion and intense monitoring (Singh et al .,2006), but there are few studies about the usage of crystalloids (Arora et al.,2020). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05220891
Study type	Observational
Source	Assiut University
Contact	Shady Elsedfy, Resident
Phone	01028790280
Email	elsdfyshady@gmail.com
Status	Not yet recruiting
Phase
Start date	January 11, 2023
Completion date	February 11, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02891642` - Liquid Biopsy With Immunomagnetic Beads Capture Technique for Malignant Cell Detection in Body Fluid
Recruiting	`NCT00239096` - Prevention of Decompensation in Liver Cirrhosis	Phase 4
Active, not recruiting	`NCT03973866` - Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study)	N/A
Terminated	`NCT01455246` - Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis	Phase 2/Phase 3
Completed	`NCT01349348` - Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites	Phase 3
Completed	`NCT01578226` - Procalcitonin in Cirrhotic Patients at High Risk for Sepsis	N/A
Terminated	`NCT00548366` - Sodium Restriction in the Management of Cirrhotic Ascites	Phase 4
Recruiting	`NCT05025878` - 13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
Completed	`NCT03327688` - Point-of-care Ultrasound in Finland	N/A
Not yet recruiting	`NCT04550091` - Role Of Multi-detector Computed Tomography In Differentiation Between Different Types Of Ascites
Completed	`NCT01769040` - Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis	Phase 4
Not yet recruiting	`NCT01716611` - Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites	Phase 4
Recruiting	`NCT05700708` - Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites
Recruiting	`NCT05511766` - Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis	Phase 2/Phase 3
Completed	`NCT05013502` - Empagliflozin in Diuretic Refractory Ascites	Phase 1
Not yet recruiting	`NCT06436807` - PMCF Study of the CE-marked Drainova® ArgentiC Catheter
Completed	`NCT03263598` - Validation of Diagnostic Usefulness of the Random Urine Na/K Ratio for Replacement of 24hr Urine Na Excretion in Cirrhotic Patients With Ascites
Completed	`NCT00907673` - The Automated Fluid Shunt (AFS)in Chronic Congestive Heart Failure	N/A
Suspended	`NCT00511394` - Acute Hemodynamics of Albumin Versus Normal Saline in Cirrhosis	N/A
Terminated	`NCT00796861` - Trial of Sunitinib for Refractory Malignant Ascites	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.